Migraine is the third most common illness in the world, with about 14 percent of the global population experiencing migraine ...

Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug ...

Although the company will lose patent exclusivity for several top drugs, it also has newer products on the market, such as cancer therapies Adcetris and Padcev along with migraine drug Nurtec ODT ...

Headaches on the right side of your head are often migraine, tension, or cluster headaches. These types of headaches (primary headaches) are not related to any underlying condition. Right-sided ...

Akili Scope achieved breakthrough status for ADHD treatment from the FDA in May 2023. In March 2023, Biohaven’s Nurtec ODT gained FDA approval for preventing migraines, becoming the sole oral ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Joe and Teresa Graedon answer letters from readers in ...

The portfolio of Royalty Pharma Plc (NASDAQ:RPRX) comprises royalties in more than 35 marketed drugs, such as Pfizer’s Nurtec ODT, Novartis’ Promacta, AbbVie and Johnson & Johnson’s ...

If your doctor prescribes orally disintegrating tablets (ODT), peel back the foil covering the tablet with dry hands. Do not push the ODT through the foil (this could cause the ODT to break).

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 ...

and Biohaven's just-approved Nurtec ODT (rimegepant) – expected to exert pressure on Lilly’s acute therapy Reyvow (lasmiditan). A first-in-class 5-HT1F receptor agonist, Reyvow was cleared by ...